+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Lacrimal Duct Stent Tube Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 5026081
  • Report
  • January 2022
  • Region: Global
  • 110 Pages
  • Mordor Intelligence


  • Aurolab
  • Bess Medizintechnik GmbH
  • FCI Ophthalmics
  • Kaneka Pharma America LLC

The Lacrimal Duct Stent Tube market studied is anticipated to grow with a CAGR of nearly 5.2%, during the forecast period.

Certain factors that are driving the market growth include Increasing patient pool for nasolacrimal duct obstruction and Rising demand for treatments with minimal invasions as well as better success rates.

Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common disorder of the lacrimal system. According to the 2020 article, titled “Nasolacrimal Duct Obstruction”, approximately 6% to 20% of newborns patients present with some symptoms. There is a high rate of spontaneous resolution of congenital nasolacrimal duct obstruction with approximately 70% of affected children being free of the symptoms by 3 months of age, and over 90% recovering by their first birthday. However, infants at increased risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital and ear anomalies) syndrome, and Goldenhar syndrome. Hence, due to the rising prevalence of such health conditions is expected to drive the market growth over the forecast period.

Key Market Trends

Bicanalicular Lacrimal Duct Stent Tube Holds Significant Share in the Global Lacrimal Duct Stent Tube Market

Bicanalicular lacrimal intubation is a successful treatment for children with nasolacrimal duct obstruction, and the younger the age of the children the higher the success rate. Bicanalicular lacrimal tubes have two probes with an intervening stent. One probe is passed through the upper punctum and the other through the lower punctum. The probes are removed, and the free ends of the silicone tube are tied in the nose and sometimes secured with a suture. The longer the duration of the tube retention the better the results, with best results between 3 and 12 months.

Over the past several years, lacrimal intubation has become a very common surgical procedure for congenital nasolacrimal duct obstruction that does not respond to conservative medical treatment or with failed probing. A few other health conditions are also associated with lacrimal duct obstruction which need to be addressed. For instance, Dacryocystitis is an infection or inflammation of the nasolacrimal sac, usually accompanied by blockage of the nasolacrimal duct. The high prevalence of such health conditions are expected to propel the market growth across the globe.

North America Dominates the Global Lacrimal Duct Stent Tube Market

North America is expected to dominate the overall market, throughout the forecast period. In the North American region, the United States holds the largest market share, and this is due to better regulations of surgical devices and growing awareness among the population to approach for such procedures in case of lacrimal duct obstruction and other associated problems. The companies also have well-established direct channel collaboration with hospitals and clinics to serve the studied market.

Competitive Landscape

The global Lacrimal Duct Stent Tube market is competitive and consists of very few major players. Companies like Aurolab, Bess Medizintechnik GmbH, FCI Ophthalmics, Gunther Weiss Scientific Glass, Kaneka Pharma America LLC, among others, hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Aurolab
  • Bess Medizintechnik GmbH
  • FCI Ophthalmics
  • Kaneka Pharma America LLC

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Patient Pool for Nasolacrimal Duct Obstruction
4.2.2 Rising Demand for Treatments with Minimal Invasions as well as Better Success Rates
4.3 Market Restraints
4.3.1 Complications Associated with Stent Tubes
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product Type
5.1.1 Monocanalicular Lacrimal Duct Stent Tube
5.1.2 Bicanalicular Lacrimal Duct Stent Tube
5.2 By End-User
5.2.1 Hospitals
5.2.2 Ophthalmic Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Aurolab
6.1.2 Bess Medizintechnik GmbH
6.1.3 FCI Ophthalmics
6.1.4 Gunther Weiss Scientific Glass
6.1.5 Kaneka Pharma America LLC
6.1.6 Becton, Dickinson and Company
6.1.7 Beaver-Visitec International, Inc
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aurolab
  • Bess Medizintechnik GmbH
  • FCI Ophthalmics
  • Gunther Weiss Scientific Glass
  • Kaneka Pharma America LLC
  • Becton, Dickinson and Company
  • Beaver-Visitec International, Inc
Note: Product cover images may vary from those shown